Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Bioventus Inc.BVS-13.741.403.9617.05-25.82%-4.80%43.80$5.88$23.346,551$11.70

Detail of Bioventus Inc.

 
CEO
Mr. Robert E. Claypoole
Employees
1030
Industry
Medical Devices
Sector
Healthcare
Market cap
$749M

Company details

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Revenue
Cost of goods
Gross profit
OE
R&D
G&A
OI
OIE
PI
TAX
NI
Revenue (Rev)
$536.89M
Cost of goods (CoG)
-$179.72M
Gross profit (GP)
$357.17M
Operating expense (OE)
-$334.23M
Research and development (R&D)
-$12.86M
General and administrative (G&A)
-$321.37M
Operating income (OI)
$14.70M
Other income expense (OIE)
-$35.17M
Pretax income (PI)
-$61.12M
Tax (TAX)
$6.58M
Net income (NI)
-$54.54M
Bioventus Inc.
BVS • XNGS • US
$11 .70
+8.62 (280.78%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$0.85
Margin profit
-7.82%
52 week low
$2.89
52 week high
$11.99
50-day simple moving average
$10.72
200-day simple moving average
$10.15
Percent held by insiders
11.51%
Percent held by institutions
65.50%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
BVS +280.78%
eps change
BVS 0.00%